Please provide your email address to receive an email when new articles are posted on . In the LOCKCYST I clinical trial, a low dose of Somatuline Depot injection for the treatment of polycystic liver ...

The FDA has approved revised labeling to include an extended dosing interval of Somatuline Depot (lanreotide; Ipsen) Injection for the treatment of acromegaly. The updated dosing recommendations allow ...

Ipsen announced that the Food and Drug Administration (FDA) has accepted and granted Priority Review to its supplemental New Drug Application (sNDA) for Somatuline Depot (lanreotide acetate) 120mg ...

Cipla has received the Food and Drug Administration’s blessing for lanreotide injection 120 mg/0.5 ml, 90 mg/0.3 ml, 60 mg/0.2 ml, which is the generic of somatuline depot (lanreotide) injection.

Clinical Benefit and Expedited Approval of Cancer Drugs in the United States, European Union, Switzerland, Japan, Canada, and Australia Randomized, single-blinded study. Patients with NETs received ...

The Food and Drug Administration has given Cipla its stamp of approval for lanreotide injection. The medication is the generic of Ipsen’s Somatuline Depot. It is indicated for the treatment of ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved a prior approval supplement application for the extended dosing interval of lanreotide ...

The Food and Drug Administration has approved Somatuline Depot (lanreotide) for the treatment of patients with unresectable, well or moderately differentiated, locally advanced or metastatic ...

“For patients who must get regular injections of Somatuline Depot, and the healthcare professionals that administer their medication, this updated design, incorporating Safe’n’Sound® syringe ...

Insulin-like growth factor I and growth hormone levels were adequately controlled on 4-weekly injections in nine patients. In these patients the effect of increasing the time interval between ...

Cipla said supplies of its key US drug Lanreotide will remain constrained after its manufacturing partner paused production following USFDA observations ...

PARIS--(BUSINESS WIRE)--Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) published today new data from seven abstracts to be presented at the hybrid-setting 19 th Annual European Neuroendocrine ...